[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fOMnQ-7fYBLFtdlUbKX0Hc_8Y9IBp6Nm-ImHdxNu5_9E":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":79,"rows":86},"University of Texas at Austin",[4],348,false,89,9,59608,10,313,[14,17,19,21,24,26,28,30],{"name":15,"count":16},"Depression",21,{"name":18,"count":9},"Healthy",{"name":20,"count":9},"Anxiety",{"name":22,"count":23},"Social Anxiety Disorder",7,{"name":25,"count":23},"Major Depressive Disorder",{"name":27,"count":23},"Hypertension",{"name":29,"count":23},"Metabolic Syndrome",{"name":31,"count":32},"Post Traumatic Stress Disorder",6,[34,39,44,49,54,59,64,69,74],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03082755","Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease","2022-08-31","Gabapentin Enacarbil",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06351124","Beta-Hydroxybutyrate Feasibility Treating IBD","2025-04-01","Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06821087","Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19","2026-05","Ketamine only",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04229758","Restarting Anticoagulation After Traumatic Intracranial Hemorrhage","2026-12","Anticoagulants",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05892744","Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression","2027-07-15","Sertraline",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07534709","Suzetrigine for Opioid-Free Recovery After Cesarean Delivery","2028-02","Suzetrigine",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06132178","Psilocybin rTMS for Treatment Resistant Depression","2029-12-31","Psilocybin",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT07369115","Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse","2030-01","Lumateperone 42 mg",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04830163","Brain State-dependent PCMS in Chronic Stroke","2030-07","Brain state-dependent paired corticomotoneuronal stimulation",[80,81,82,83,84,85],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[87,112,137,158,180,205,227,249,271,296,314,342,360,389,407,431,458,476,500,524,554,572,590,616,642,670,688,706,731,755,794,823,849,874,898,916,934,979,1004,1027,1053,1071,1098,1125],{"intervention":73,"totalTrials":88,"cells":89},1,{"EARLY_PHASE1":90,"PHASE1":93,"PHASE2":95,"PHASE3":97,"PHASE4":99,"NA":110},{"trials":91,"activeCount":92},[],0,{"trials":94,"activeCount":92},[],{"trials":96,"activeCount":92},[],{"trials":98,"activeCount":92},[],{"trials":100,"activeCount":88,"soonestReadout":72},[101],{"nctId":70,"briefTitle":71,"status":102,"phases":103,"primaryCompletion":72,"completion":72,"start":104,"enrollment":105,"conditions":106,"interventions":109},"NOT_YET_RECRUITING",[84],"2026-02",50,[107,108],"Major Depressive Diorder","Early Life Trauma",[73],{"trials":111,"activeCount":92},[],{"intervention":63,"totalTrials":88,"cells":113},{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":135},{"trials":115,"activeCount":92},[],{"trials":117,"activeCount":92},[],{"trials":119,"activeCount":92},[],{"trials":121,"activeCount":92},[],{"trials":123,"activeCount":88,"soonestReadout":62},[124],{"nctId":60,"briefTitle":61,"status":102,"phases":125,"primaryCompletion":62,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":134},[84],"2028-05","2026-06",90,[130,131,132,133],"Cesarean Delivery","Cesarean Section","Pain, Postoperative","Opioid Consumption, Postoperative",[63],{"trials":136,"activeCount":92},[],{"intervention":58,"totalTrials":88,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":156},{"trials":140,"activeCount":92},[],{"trials":142,"activeCount":92},[],{"trials":144,"activeCount":92},[],{"trials":146,"activeCount":92},[],{"trials":148,"activeCount":88,"soonestReadout":57},[149],{"nctId":55,"briefTitle":56,"status":150,"phases":151,"primaryCompletion":57,"completion":57,"start":152,"enrollment":105,"conditions":153,"interventions":155},"RECRUITING",[84],"2023-09-30",[25,154],"Chronic Major Depression, Recurrent",[58],{"trials":157,"activeCount":92},[],{"intervention":38,"totalTrials":88,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":178},{"trials":161,"activeCount":92},[],{"trials":163,"activeCount":92},[],{"trials":165,"activeCount":92},[],{"trials":167,"activeCount":92},[],{"trials":169,"activeCount":88,"soonestReadout":37},[170],{"nctId":35,"briefTitle":36,"status":150,"phases":171,"primaryCompletion":37,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":177},[84],"2023-03-31","2017-07-01",156,[176],"Alzheimer Disease",[38],{"trials":179,"activeCount":92},[],{"intervention":53,"totalTrials":88,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":201,"NA":203},{"trials":183,"activeCount":92},[],{"trials":185,"activeCount":92},[],{"trials":187,"activeCount":92},[],{"trials":189,"activeCount":88,"soonestReadout":52},[190],{"nctId":50,"briefTitle":51,"status":102,"phases":191,"primaryCompletion":52,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":200},[83],"2027-02","2021-10",1100,[196,197,198,199],"Hemorrhage","Intracranial Hemorrhages","Bleeding","Trauma",[53],{"trials":202,"activeCount":92},[],{"trials":204,"activeCount":92},[],{"intervention":78,"totalTrials":88,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":221,"PHASE4":223,"NA":225},{"trials":208,"activeCount":92},[],{"trials":210,"activeCount":92},[],{"trials":212,"activeCount":88,"soonestReadout":77},[213],{"nctId":75,"briefTitle":76,"status":102,"phases":214,"primaryCompletion":77,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},[81,82],"2031-07","2026-01-01",45,[219],"Stroke",[78],{"trials":222,"activeCount":92},[],{"trials":224,"activeCount":92},[],{"trials":226,"activeCount":92},[],{"intervention":48,"totalTrials":88,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":243,"PHASE4":245,"NA":247},{"trials":230,"activeCount":92},[],{"trials":232,"activeCount":92},[],{"trials":234,"activeCount":88,"soonestReadout":47},[235],{"nctId":45,"briefTitle":46,"status":236,"phases":237,"primaryCompletion":47,"completion":47,"start":238,"enrollment":239,"conditions":240,"interventions":242},"ENROLLING_BY_INVITATION",[82],"2025-04-28",20,[241],"Long COVID",[48],{"trials":244,"activeCount":92},[],{"trials":246,"activeCount":92},[],{"trials":248,"activeCount":92},[],{"intervention":43,"totalTrials":88,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":265,"PHASE4":267,"NA":269},{"trials":252,"activeCount":92},[],{"trials":254,"activeCount":92},[],{"trials":256,"activeCount":88,"soonestReadout":42},[257],{"nctId":40,"briefTitle":41,"status":150,"phases":258,"primaryCompletion":42,"completion":259,"start":260,"enrollment":239,"conditions":261,"interventions":264},[81,82],"2025-12-31","2024-08-28",[262,263],"Crohn's Disease","Inflammatory Bowel Diseases",[43],{"trials":266,"activeCount":92},[],{"trials":268,"activeCount":92},[],{"trials":270,"activeCount":92},[],{"intervention":68,"totalTrials":88,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":290,"PHASE4":292,"NA":294},{"trials":274,"activeCount":92},[],{"trials":276,"activeCount":92},[],{"trials":278,"activeCount":88,"soonestReadout":67},[279],{"nctId":65,"briefTitle":66,"status":150,"phases":280,"primaryCompletion":67,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":288},[82],"2030-12-31","2025-01-10",100,[285,286,25,287,15],"Treatment Resistant Depression","MDD","Recurrent Depression",[68,289],"Low-dose psilocybin",{"trials":291,"activeCount":92},[],{"trials":293,"activeCount":92},[],{"trials":295,"activeCount":92},[],{"intervention":289,"totalTrials":88,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":299,"activeCount":92},[],{"trials":301,"activeCount":92},[],{"trials":303,"activeCount":88,"soonestReadout":67},[304],{"nctId":65,"briefTitle":66,"status":150,"phases":305,"primaryCompletion":67,"completion":281,"start":282,"enrollment":283,"conditions":306,"interventions":307},[82],[285,286,25,287,15],[68,289],{"trials":309,"activeCount":92},[],{"trials":311,"activeCount":92},[],{"trials":313,"activeCount":92},[],{"intervention":315,"totalTrials":88,"cells":316},"testosterone propionate",{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":340},{"trials":318,"activeCount":92},[],{"trials":320,"activeCount":92},[],{"trials":322,"activeCount":92},[],{"trials":324,"activeCount":92},[],{"trials":326,"activeCount":92},[327],{"nctId":328,"briefTitle":329,"status":330,"phases":331,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":338},"NCT04865562","Hormones and Decision Making","COMPLETED",[84],"2016-05-01","2016-09-01","2015-03-01",30,[337],"Dyssocial Behavior",[315,339],"0.5% cholorbutanol, saline",{"trials":341,"activeCount":92},[],{"intervention":339,"totalTrials":88,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":358},{"trials":345,"activeCount":92},[],{"trials":347,"activeCount":92},[],{"trials":349,"activeCount":92},[],{"trials":351,"activeCount":92},[],{"trials":353,"activeCount":92},[354],{"nctId":328,"briefTitle":329,"status":330,"phases":355,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":356,"interventions":357},[84],[337],[315,339],{"trials":359,"activeCount":92},[],{"intervention":361,"totalTrials":88,"cells":362},"50 Micrograms Vaginal Misoprostol",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":387},{"trials":364,"activeCount":92},[],{"trials":366,"activeCount":92},[],{"trials":368,"activeCount":92},[],{"trials":370,"activeCount":92},[],{"trials":372,"activeCount":92},[373],{"nctId":374,"briefTitle":375,"status":330,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":385},"NCT05262738","Misoprostol Dosing in BMI Greater Than 30",[84],"2023-07-14","2023-07-17","2022-06-01",180,[382,383,384],"Pregnancy Related","Obesity","Labor Onset and Length Abnormalities",[361,386],"25 Micrograms Vaginal Misoprostol",{"trials":388,"activeCount":92},[],{"intervention":386,"totalTrials":88,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":405},{"trials":392,"activeCount":92},[],{"trials":394,"activeCount":92},[],{"trials":396,"activeCount":92},[],{"trials":398,"activeCount":92},[],{"trials":400,"activeCount":92},[401],{"nctId":374,"briefTitle":375,"status":330,"phases":402,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":403,"interventions":404},[84],[382,383,384],[361,386],{"trials":406,"activeCount":92},[],{"intervention":408,"totalTrials":88,"cells":409},"HPA, ANS stimulation",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":429},{"trials":411,"activeCount":92},[],{"trials":413,"activeCount":92},[],{"trials":415,"activeCount":92},[],{"trials":417,"activeCount":92},[],{"trials":419,"activeCount":92},[420],{"nctId":421,"briefTitle":422,"status":330,"phases":423,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":428},"NCT02372110","Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response",[84],"2015-11","2015-03",120,[20],[408],{"trials":430,"activeCount":92},[],{"intervention":432,"totalTrials":88,"cells":433},"Liposomal Bupivacaine",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":456},{"trials":435,"activeCount":92},[],{"trials":437,"activeCount":92},[],{"trials":439,"activeCount":92},[],{"trials":441,"activeCount":92},[],{"trials":443,"activeCount":92},[444],{"nctId":445,"briefTitle":446,"status":447,"phases":448,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":454},"NCT03844451","Enhanced Recovery With Liposomal Bupivacaine in Orthognathic Surgery","UNKNOWN",[84],"2019-09-01","2019-11-01","2019-05-17",75,[132],[432,455],"Bupivacaine and Epinephrine",{"trials":457,"activeCount":92},[],{"intervention":455,"totalTrials":88,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":474},{"trials":461,"activeCount":92},[],{"trials":463,"activeCount":92},[],{"trials":465,"activeCount":92},[],{"trials":467,"activeCount":92},[],{"trials":469,"activeCount":92},[470],{"nctId":445,"briefTitle":446,"status":447,"phases":471,"primaryCompletion":449,"completion":450,"start":451,"enrollment":452,"conditions":472,"interventions":473},[84],[132],[432,455],{"trials":475,"activeCount":92},[],{"intervention":477,"totalTrials":88,"cells":478},"Influenza Vaccine",{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":498},{"trials":480,"activeCount":92},[],{"trials":482,"activeCount":92},[],{"trials":484,"activeCount":92},[],{"trials":486,"activeCount":92},[],{"trials":488,"activeCount":92},[489],{"nctId":490,"briefTitle":491,"status":447,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":452,"conditions":496,"interventions":497},"NCT03756246","Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression",[84],"2020-05","2021-05","2019-06-10",[15,18],[477],{"trials":499,"activeCount":92},[],{"intervention":501,"totalTrials":88,"cells":502},"Apixaban",{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":520,"NA":522},{"trials":504,"activeCount":92},[],{"trials":506,"activeCount":92},[],{"trials":508,"activeCount":92},[],{"trials":510,"activeCount":92},[511],{"nctId":512,"briefTitle":513,"status":447,"phases":514,"primaryCompletion":515,"completion":515,"start":516,"enrollment":283,"conditions":517,"interventions":519},"NCT04891861","Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage",[83],"2023-07-01","2021-07-01",[518],"Anticoagulants; Increased",[501],{"trials":521,"activeCount":92},[],{"trials":523,"activeCount":92},[],{"intervention":525,"totalTrials":88,"cells":526},"Sucralfate",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":528,"activeCount":92},[],{"trials":530,"activeCount":92},[],{"trials":532,"activeCount":92},[533],{"nctId":534,"briefTitle":535,"status":330,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":545},"NCT03241030","Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial",[82],"2018-07-31","2019-06-20","2017-09-12",102,[542,543,544],"Herpangina","Gingivostomatitis","Hand, Foot and Mouth Disease",[525,546,547],"Acetaminophen","Ibuprofen",{"trials":549,"activeCount":92},[],{"trials":551,"activeCount":92},[],{"trials":553,"activeCount":92},[],{"intervention":546,"totalTrials":88,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":557,"activeCount":92},[],{"trials":559,"activeCount":92},[],{"trials":561,"activeCount":92},[562],{"nctId":534,"briefTitle":535,"status":330,"phases":563,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":564,"interventions":565},[82],[542,543,544],[525,546,547],{"trials":567,"activeCount":92},[],{"trials":569,"activeCount":92},[],{"trials":571,"activeCount":92},[],{"intervention":547,"totalTrials":88,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":584,"PHASE4":586,"NA":588},{"trials":575,"activeCount":92},[],{"trials":577,"activeCount":92},[],{"trials":579,"activeCount":92},[580],{"nctId":534,"briefTitle":535,"status":330,"phases":581,"primaryCompletion":537,"completion":538,"start":539,"enrollment":540,"conditions":582,"interventions":583},[82],[542,543,544],[525,546,547],{"trials":585,"activeCount":92},[],{"trials":587,"activeCount":92},[],{"trials":589,"activeCount":92},[],{"intervention":591,"totalTrials":88,"cells":592},"CBD Isolate",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":610,"PHASE4":612,"NA":614},{"trials":594,"activeCount":92},[],{"trials":596,"activeCount":92},[],{"trials":598,"activeCount":92},[599],{"nctId":600,"briefTitle":601,"status":602,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":609},"NCT04197102","Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder","SUSPENDED",[82],"2024-05","2025-05","2020-01-15",150,[31],[591],{"trials":611,"activeCount":92},[],{"trials":613,"activeCount":92},[],{"trials":615,"activeCount":92},[],{"intervention":617,"totalTrials":88,"cells":618},"Nicotine transdermal patch",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":620,"activeCount":92},[],{"trials":622,"activeCount":92},[623],{"nctId":624,"briefTitle":625,"status":330,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT00833404","Smoking Cessation and Sexual Health in Men",[81],"2010-01","2010-12","2008-12",80,[632],"Smoking Cessation",[617],{"trials":635,"activeCount":92},[],{"trials":637,"activeCount":92},[],{"trials":639,"activeCount":92},[],{"trials":641,"activeCount":92},[],{"intervention":643,"totalTrials":88,"cells":644},"E-cigarette",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":662,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":646,"activeCount":92},[],{"trials":648,"activeCount":92},[649],{"nctId":650,"briefTitle":651,"status":330,"phases":652,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":659},"NCT03209661","Vascular Effects of a Single Bout of Electronic Cigarette Use",[81],"2018-08-01","2018-08-31","2017-04-28",16,[658],"Arterial Stiffness",[643,660,661],"Nicotine 0%","Menthol Inhalant Product",{"trials":663,"activeCount":92},[],{"trials":665,"activeCount":92},[],{"trials":667,"activeCount":92},[],{"trials":669,"activeCount":92},[],{"intervention":660,"totalTrials":88,"cells":671},{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":673,"activeCount":92},[],{"trials":675,"activeCount":92},[676],{"nctId":650,"briefTitle":651,"status":330,"phases":677,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":678,"interventions":679},[81],[658],[643,660,661],{"trials":681,"activeCount":92},[],{"trials":683,"activeCount":92},[],{"trials":685,"activeCount":92},[],{"trials":687,"activeCount":92},[],{"intervention":661,"totalTrials":88,"cells":689},{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":698,"PHASE3":700,"PHASE4":702,"NA":704},{"trials":691,"activeCount":92},[],{"trials":693,"activeCount":92},[694],{"nctId":650,"briefTitle":651,"status":330,"phases":695,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":696,"interventions":697},[81],[658],[643,660,661],{"trials":699,"activeCount":92},[],{"trials":701,"activeCount":92},[],{"trials":703,"activeCount":92},[],{"trials":705,"activeCount":92},[],{"intervention":707,"totalTrials":88,"cells":708},"Dexrazoxane",{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":710,"activeCount":92},[],{"trials":712,"activeCount":92},[713],{"nctId":714,"briefTitle":715,"status":447,"phases":716,"primaryCompletion":193,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT04997291","Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery",[81],"2022-01","2021-04-09",12,[721],"Heart Defects, Congenital",[707],{"trials":724,"activeCount":92},[],{"trials":726,"activeCount":92},[],{"trials":728,"activeCount":92},[],{"trials":730,"activeCount":92},[],{"intervention":732,"totalTrials":88,"cells":733},"Caffeine",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":753},{"trials":735,"activeCount":92},[],{"trials":737,"activeCount":92},[738],{"nctId":739,"briefTitle":740,"status":330,"phases":741,"primaryCompletion":742,"completion":742,"start":743,"enrollment":239,"conditions":744,"interventions":746},"NCT05685407","Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women",[81],"2023-04-15","2023-01-01",[745],"Female Sexual Arousal Disorder",[732],{"trials":748,"activeCount":92},[],{"trials":750,"activeCount":92},[],{"trials":752,"activeCount":92},[],{"trials":754,"activeCount":92},[],{"intervention":756,"totalTrials":757,"cells":758},"D-Cycloserine",2,{"EARLY_PHASE1":759,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":760,"activeCount":92},[761,770],{"nctId":762,"briefTitle":763,"status":330,"phases":764,"primaryCompletion":765,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":769},"NCT02066792","Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder",[80],"2018-07-01","2014-04",152,[22],[756],{"nctId":771,"briefTitle":772,"status":330,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":780},"NCT01944423","Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine",[80],"2018-10","2013-10",53,[778,779],"Nicotine Addiction","Panic Attack",[781,782,783],"d-cycloserine","Pill Placebo","Nicotine replacement therapy",{"trials":785,"activeCount":92},[],{"trials":787,"activeCount":92},[],{"trials":789,"activeCount":92},[],{"trials":791,"activeCount":92},[],{"trials":793,"activeCount":92},[],{"intervention":795,"totalTrials":88,"cells":796},"Isradipine",{"EARLY_PHASE1":797,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":821},{"trials":798,"activeCount":92},[799],{"nctId":800,"briefTitle":801,"status":330,"phases":802,"primaryCompletion":803,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":812},"NCT03083353","Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation",[80],"2023-06-14","2020-01-22",78,[807,808,632,809,810,811],"Nicotine Dependence","Smoking, Cigarette","Smoking Behaviors","Smoking Reduction","Craving",[795],{"trials":814,"activeCount":92},[],{"trials":816,"activeCount":92},[],{"trials":818,"activeCount":92},[],{"trials":820,"activeCount":92},[],{"trials":822,"activeCount":92},[],{"intervention":824,"totalTrials":88,"cells":825},"Prehabilitation Program",{"EARLY_PHASE1":826,"PHASE1":839,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":827,"activeCount":92},[828],{"nctId":829,"briefTitle":830,"status":330,"phases":831,"primaryCompletion":832,"completion":833,"start":834,"enrollment":835,"conditions":836,"interventions":838},"NCT04073381","Application of Ergogenic Aids to the Prehabilitation of Abdominal Cancer Patients Undergoing Cancer Surgery",[80],"2020-07-31","2020-08-31","2018-10-28",92,[837],"Prehabilitation",[824],{"trials":840,"activeCount":92},[],{"trials":842,"activeCount":92},[],{"trials":844,"activeCount":92},[],{"trials":846,"activeCount":92},[],{"trials":848,"activeCount":92},[],{"intervention":850,"totalTrials":88,"cells":851},"Dexamethasone",{"EARLY_PHASE1":852,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":853,"activeCount":92},[854],{"nctId":855,"briefTitle":856,"status":447,"phases":857,"primaryCompletion":858,"completion":859,"start":515,"enrollment":860,"conditions":861,"interventions":863},"NCT05287035","Spinal Fusions Steroid Study",[80],"2025-01-01","2025-07-01",70,[862],"Spinal Fusion",[850],{"trials":865,"activeCount":92},[],{"trials":867,"activeCount":92},[],{"trials":869,"activeCount":92},[],{"trials":871,"activeCount":92},[],{"trials":873,"activeCount":92},[],{"intervention":875,"totalTrials":88,"cells":876},"Oxytocin",{"EARLY_PHASE1":877,"PHASE1":888,"PHASE2":890,"PHASE3":892,"PHASE4":894,"NA":896},{"trials":878,"activeCount":92},[879],{"nctId":880,"briefTitle":881,"status":882,"phases":883,"primaryCompletion":884,"completion":884,"start":885,"enrollment":92,"conditions":886,"interventions":887},"NCT02361177","Role of Oxytocin in Telling and Detecting Lies","WITHDRAWN",[80],"2016-04","2016-01",[337],[875],{"trials":889,"activeCount":92},[],{"trials":891,"activeCount":92},[],{"trials":893,"activeCount":92},[],{"trials":895,"activeCount":92},[],{"trials":897,"activeCount":92},[],{"intervention":782,"totalTrials":88,"cells":899},{"EARLY_PHASE1":900,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":914},{"trials":901,"activeCount":92},[902],{"nctId":771,"briefTitle":772,"status":330,"phases":903,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":904,"interventions":905},[80],[778,779],[781,782,783],{"trials":907,"activeCount":92},[],{"trials":909,"activeCount":92},[],{"trials":911,"activeCount":92},[],{"trials":913,"activeCount":92},[],{"trials":915,"activeCount":92},[],{"intervention":783,"totalTrials":88,"cells":917},{"EARLY_PHASE1":918,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":919,"activeCount":92},[920],{"nctId":771,"briefTitle":772,"status":330,"phases":921,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":922,"interventions":923},[80],[778,779],[781,782,783],{"trials":925,"activeCount":92},[],{"trials":927,"activeCount":92},[],{"trials":929,"activeCount":92},[],{"trials":931,"activeCount":92},[],{"trials":933,"activeCount":92},[],{"intervention":935,"totalTrials":936,"cells":937},"Testosterone",3,{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":959},{"trials":939,"activeCount":92},[],{"trials":941,"activeCount":92},[],{"trials":943,"activeCount":92},[],{"trials":945,"activeCount":92},[],{"trials":947,"activeCount":92},[948],{"nctId":949,"briefTitle":950,"status":330,"phases":951,"primaryCompletion":952,"completion":953,"start":954,"enrollment":955,"conditions":956,"interventions":958},"NCT02799277","A Multinomial Process Model of Moral Judgment",[84],"2018-05-05","2018-06-01","2017-08-30",220,[935,957],"Placebos",[935],{"trials":960,"activeCount":92},[961,970],{"nctId":962,"briefTitle":963,"status":330,"phases":964,"primaryCompletion":965,"completion":965,"start":966,"enrollment":426,"conditions":967,"interventions":969},"NCT01408498","Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance",[85],"2012-04","2012-01",[968],"Testosterone's Effects on Threat Perception\u002FResponse",[935],{"nctId":971,"briefTitle":972,"status":330,"phases":973,"primaryCompletion":884,"completion":974,"start":975,"enrollment":976,"conditions":977,"interventions":978},"NCT02361190","Effects of Fast Acting Testosterone Nasal Spray on Anxiety",[85],"2016-05","2015-02",96,[20],[935],{"intervention":980,"totalTrials":88,"cells":981},"Hydrocortisone",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":988,"PHASE4":990,"NA":992},{"trials":983,"activeCount":92},[],{"trials":985,"activeCount":92},[],{"trials":987,"activeCount":92},[],{"trials":989,"activeCount":92},[],{"trials":991,"activeCount":92},[],{"trials":993,"activeCount":92},[994],{"nctId":995,"briefTitle":996,"status":330,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":426,"conditions":1001,"interventions":1003},"NCT01710202","Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration",[],"2013-12","2014-11","2012-10",[25,1002],"Anxiety Disorders",[980],{"intervention":1005,"totalTrials":88,"cells":1006},"Insulin",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1017},{"trials":1008,"activeCount":92},[],{"trials":1010,"activeCount":92},[],{"trials":1012,"activeCount":92},[],{"trials":1014,"activeCount":92},[],{"trials":1016,"activeCount":92},[],{"trials":1018,"activeCount":92},[1019],{"nctId":1020,"briefTitle":1021,"status":330,"phases":1022,"primaryCompletion":766,"completion":766,"start":1023,"enrollment":719,"conditions":1024,"interventions":1026},"NCT01145482","Mechanisms of Insulin Facilitation of Memory",[85],"2010-07",[1025],"Memory Disorders",[1005],{"intervention":1028,"totalTrials":88,"cells":1029},"Intranasal Fentanyl Spray and Intranasal Midazolam Spray",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1038,"NA":1040},{"trials":1031,"activeCount":92},[],{"trials":1033,"activeCount":92},[],{"trials":1035,"activeCount":92},[],{"trials":1037,"activeCount":92},[],{"trials":1039,"activeCount":92},[],{"trials":1041,"activeCount":92},[1042],{"nctId":1043,"briefTitle":1044,"status":447,"phases":1045,"primaryCompletion":1046,"completion":1047,"start":1048,"enrollment":283,"conditions":1049,"interventions":1051},"NCT04745260","Intranasal Fentanyl in Combination With Midazolam Versus Midazolam Alone for Pediatric Facial Laceration Repair",[85],"2021-11-01","2021-12-31","2021-03-01",[1050,20],"Facial Laceration",[1028,1052],"Intranasal Midazolam Spray",{"intervention":1052,"totalTrials":88,"cells":1054},{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1065},{"trials":1056,"activeCount":92},[],{"trials":1058,"activeCount":92},[],{"trials":1060,"activeCount":92},[],{"trials":1062,"activeCount":92},[],{"trials":1064,"activeCount":92},[],{"trials":1066,"activeCount":92},[1067],{"nctId":1043,"briefTitle":1044,"status":447,"phases":1068,"primaryCompletion":1046,"completion":1047,"start":1048,"enrollment":283,"conditions":1069,"interventions":1070},[85],[1050,20],[1028,1052],{"intervention":1072,"totalTrials":88,"cells":1073},"NaHCO3",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1075,"activeCount":92},[],{"trials":1077,"activeCount":92},[],{"trials":1079,"activeCount":92},[],{"trials":1081,"activeCount":92},[],{"trials":1083,"activeCount":92},[],{"trials":1085,"activeCount":92},[1086],{"nctId":1087,"briefTitle":1088,"status":330,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1097},"NCT06046924","Dietary Acid Reduction and Progression of Chronic Kidney Disease",[85],"2006-11-15","2011-12-15","1996-06-24",153,[1095,1096,27],"Chronic Kidney Diseases","Cardiovascular Diseases",[1072],{"intervention":1099,"totalTrials":88,"cells":1100},"Lidocaine",{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1102,"activeCount":92},[],{"trials":1104,"activeCount":92},[],{"trials":1106,"activeCount":92},[],{"trials":1108,"activeCount":92},[],{"trials":1110,"activeCount":92},[],{"trials":1112,"activeCount":92},[1113],{"nctId":1114,"briefTitle":1115,"status":330,"phases":1116,"primaryCompletion":515,"completion":515,"start":1117,"enrollment":1118,"conditions":1119,"interventions":1123},"NCT06188221","Does Adding Lidocaine to Corticosteroid Injections Reduce Pain Intensity in Hand Surgery",[85],"2020-02-01",40,[1120,1121,1122],"Hand Osteoarthritis","Trigger Finger","Carpal Tunnel Syndrome",[1099,1124],"Corticoids",{"intervention":1124,"totalTrials":88,"cells":1126},{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1128,"activeCount":92},[],{"trials":1130,"activeCount":92},[],{"trials":1132,"activeCount":92},[],{"trials":1134,"activeCount":92},[],{"trials":1136,"activeCount":92},[],{"trials":1138,"activeCount":92},[1139],{"nctId":1114,"briefTitle":1115,"status":330,"phases":1140,"primaryCompletion":515,"completion":515,"start":1117,"enrollment":1118,"conditions":1141,"interventions":1142},[85],[1120,1121,1122],[1099,1124]]